The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
The Design of Inhibitors for Medicinally Relevant Metalloproteins
Abstract
A number of metalloproteins are important medicinal targets for conditions ranging from pathogenic infections to cancer. Many but not all of these metalloproteins contain a zinc(II) ion in the protein active site. Small‐molecule inhibitors of these metalloproteins are designed to bind directly to the active site metal ions. In this review several metalloproteins of interest are discussed, including matrix metalloproteinases (MMPs), histone deacetylases (HDACs), anthrax lethal factor (LF), and others. Different strategies that have been employed to design effective inhibitors against these proteins are described, with an effort to highlight the strengths and drawbacks of each approach. An emphasis is placed on examining the bioinorganic chemistry of these metal active sites and how a better understanding of the coordination chemistry in these systems may lead to improved inhibitors. It is hoped that this review will help inspire medicinal, biological, and inorganic chemists to tackle this important problem by considering all aspects of metalloprotein inhibitor design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In most cases, a drug molecule establishes coordination bonds with the zinc ion10 present in the protein”
From AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins (2014) · cites this paper as [10]
Citations
Cites
Miller, M. B., & Bassler, B. L. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.165 · Cited by 5,105
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Botulinum Toxin as a Biological Weapon: Medical and Public Health Management
Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., et al. (2001) · JAMA · doi:10.1001/jama.285.8.1059 · Cited by 1,814
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Research works printed but not linked: 12
- Rybacki J. J., 2005, The essential guide to prescription drugs
- Stetler‐Stevenson W. G., 1996, Am. J. Pathol., 148, 1345
- Montgomery A. M., 1994, Cancer Res., 54, 5467
- Reich R., 1988, Cancer Res., 48, 3307
- Jong G. P., 2006, Chin. J. Physiol., 49, 104
- 10.1172/JCI22304 · doi:10.1172/jci22304 · Paper page
- Cataldo D. D., 2003, Cell. Mol. Biol., 49, 875
- Matter H., 2004, Curr. Opin. Drug Discovery Dev., 7, 513
- Parkkila S., 2000, The carbonic anhydrases: new horizons
- Liao S. Y., 1994, Am. J. Pathol., 145, 598
- Lewis C., 2002, FDA Consum., 36, 11
- 10.1172/JCI20195 · doi:10.1172/jci20195 · Paper page
Cited by
Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology
Haas, K. L., & Franz, K. J. (2009) · Chemical Reviews · doi:10.1021/cr900134a · Cited by 984
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins
Santos-Martins, D., Forli, S., Ramos, M. J., & Olson, A. J. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500209e · Cited by 318
MMPs as therapeutic targets—Still a viable option?
FINGLETON, B. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2007.06.006 · Cited by 279
Dormán, G., Cseh, S., Hajdú, I., Barna, L., Kónya, D., Kupai, K., Kovács, L., & Ferdinandy, P. (2010) · Drugs · doi:10.2165/11318390-000000000-00000 · Cited by 178
“As a viable solution, a combined approach was developed([20]) that carries out the fragment screening by ESI-MS first and then runs the NMR of the hits to identify the mode of action and major interactions.”
Microbial and fungal protease inhibitors—current and potential applications
Sabotič, J., & Kos, J. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3834-x · Cited by 174
“Therefore, much has been invested in the search for an effective protease inhibitor for use in treatment (Jacobsen et al. 2007), but none has yet been developed, which would be used in clinic.”
BackgroundLiu, J., & Khalil, R. A. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.04.003 · Cited by 170
Benjamin, M. M., & Khalil, R. A. (2012) · Experientia Supplementum · doi:10.1007/978-3-0348-0364-9_7 · Cited by 168
“These ZBGs have some features in common with hydroxamic acids but with better biostability and tighter Zn2+ binding due to ligand rigidity and, in some cases, the incorporation of sulfur donor atoms (Puerta and Cohen, 2003; Jacobsen et al., 2007).”
BackgroundCapzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11
Li, J., Yakushi, T., Parlati, F., Mackinnon, A. L., Perez, C., Ma, Y., Carter, K. P., Colayco, S., Magnuson, G., Brown, B., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2326 · Cited by 159
Self-citationWong, A. H. M., Zhou, D., & Rini, J. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.398842 · Cited by 147
“Similar zinc-carboxylate interactions have been observed in the structures of many other zinc-dependent proteases (59).”
BackgroundZinc‐Binding Groups Modulate Selective Inhibition of MMPs
Agrawal, A., Romero‐Perez, D., Jacobsen, J. A., Villarreal, F. J., & Cohen, S. M. (2008) · ChemMedChem · doi:10.1002/cmdc.200700290 · Cited by 143
Self-citationThe Design of Inhibitors for Medicinally Relevant Metalloproteins
Jacobsen, F. E., Lewis, J. A., & Cohen, S. M. (2007) · ChemInform · doi:10.1002/chin.200719261 · Cited by 117
Self-citationRouffet, M., de Oliveira, C. A. F., Udi, Y., Agrawal, A., Sagi, I., McCammon, J. A., & Cohen, S. M. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101088j · Cited by 118
Self-citationHu, M., Li, J., & Yao, S. Q. (2008) · Organic Letters · doi:10.1021/ol802286g · Cited by 133
New approaches for medicinal applications of bioinorganic chemistry
Cohen, S. M. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.01.012 · Cited by 110
Self-citationMatrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Küçükgüven, A., & Khalil, R. A. (2013) · Current Drug Targets · doi:10.2174/138945013804998972 · Cited by 125
Hanif, M., Henke, H., Meier, S. M., Martić, S., Labib, M., Kandioller, W., Jakupec, M. A., Arion, V. B., Kraatz, H., Keppler, B. K., et al. (2010) · Inorganic Chemistry · doi:10.1021/ic1009785 · Cited by 104
A patent review of IDO1 inhibitors for cancer
Cheong, J. E., Ekkati, A. R., & Sun, L. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1441290 · Cited by 107
Insight into the structural determinants for selective inhibition of matrix metalloproteinases
Pirard, B. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.06.003 · Cited by 100
Georgiadis, D., & Yiotakis, A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.058 · Cited by 106
DNA-Encoded Chemical Libraries for the Discovery of MMP-3 Inhibitors
Scheuermann, J., Dumelin, C. E., Melkko, S., Zhang, Y., Mannocci, L., Jaggi, M., Sobek, J., & Neri, D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004347 · Cited by 90
Tremlett, W. D. J., Goodman, D. M., Steel, T. R., Kumar, S., Wieczorek, A., Walsh, F. P., Sullivan, M. P., Hanif, M., & Hartinger, C. G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213950 · Cited by 94
Matrix metalloproteinases in pro-atherosclerotic arterial remodeling
Myasoedova, V. A., Chistiakov, D. A., Grechko, A. V., & Orekhov, A. N. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.08.026 · Cited by 88
Chelator Fragment Libraries for Targeting Metalloproteinases
Agrawal, A., Johnson, S. L., Jacobsen, J. A., Miller, M. T., Chen, L., Pellecchia, M., & Cohen, S. M. (2010) · ChemMedChem · doi:10.1002/cmdc.200900516 · Cited by 78
Self-citationLysine biosynthesis in bacteria: a metallodesuccinylase as a potential antimicrobial target
Gillner, D., Becker, D. P., & Holz, R. C. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0965-1 · Cited by 74
3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition
Patil, V., Sodji, Q. H., Kornacki, J. R., Mrksich, M., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301769u · Cited by 75
Modeling of metal interaction geometries for protein–ligand docking
Seebeck, B., Reulecke, I., Kämper, A., & Rarey, M. (2008) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21818 · Cited by 67
Emerging trends in metalloprotein inhibition
Rouffet, M., & Cohen, S. M. (2011) · Dalton Transactions · doi:10.1039/c0dt01743d · Cited by 77
Self-citationDeng, L., Sundriyal, S., Rubio, V., Shi, Z.-Z., & Song, Y. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9012592 · Cited by 65
Chaskar, P., Zoete, V., & Röhrig, U. F. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5004152 · Cited by 73
Enzyme Inhibition and Bioapplications
Sharma, R. (2012) · InTech eBooks · doi:10.5772/1963 · Cited by 65
Lingott, T., Schleberger, C., Gutiérrez, J. M., & Merfort, I. (2009) · Biochemistry · doi:10.1021/bi9002315 · Cited by 59
Nuti, E., Panelli, L., Casalini, F., Avramova, S. I., Orlandini, E., Santamaria, S., Nencetti, S., Tuccinardi, T., Martinelli, A., Cercignani, G., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900335a · Cited by 56
Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents
Ye, R., Tan, C., Chen, B.-C., Li, R., & Mao, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00402 · Cited by 57
“Manymetalloenzymes have been proven to be important targets for cancer therapy, and some of these metalloenzymes contain a zinc(II) ion at the active site of the enzyme (Jacobsen et al., 2007).”
BackgroundTomlinson, M. L., Guan, P., Morris, R. J., Fidock, M. D., Rejzek, M., García‐Morales, C., Field, R. A., & Wheeler, G. N. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.12.005 · Cited by 56
Gilbert, A. M., Bursavich, M. G., Lombardi, S., Georgiadis, K. E., Reifenberg, E., Flannery, C. R., & Morris, E. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.065 · Cited by 48
Rubino, M. T., Agamennone, M., Campestre, C., Campiglia, P., Cremasco, V., Faccio, R., Laghezza, A., Loiodice, F., Maggi, D., Panza, E., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201000540 · Cited by 48
Zhang, Y., Fan, X., Yang, S., Scannevin, R. H., Burke, S. L., Rhodes, K. J., & Jackson, P. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.049 · Cited by 43
Dour, G. L., Moroy, G., Rouffet, M., Bourguet, E., Guillaume, D. M., Decarme, M., Mourabit, H. E., Augé, F., Alix, A. J. P., Laronze, J., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.041 · Cited by 41
Discovery of a Potent Inhibitor Class with High Selectivity toward Clostridial Collagenases
Schönauer, E., Kany, A. M., Haupenthal, J., Hüsecken, K., Hoppe, I. J., Voos, K., Yahiaoui, S., Elsässer, B., Ducho, C., Brandstetter, H., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b06935 · Cited by 43
Hoffman, A., Qadri, B., Frant, J., Katz, Y., Bhusare, S. R., Breuer, E., Hadar, R., & Reich, R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701087n · Cited by 41
2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases
Chen, P., Banks, L. D., Mikulski, R. L., Deng, L., Sundriyal, S., Palzkill, T. G., & Song, Y. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.012 · Cited by 39
Zhang, Y., Fan, X., Chakaravarty, D., Xiang, B., Scannevin, R. H., Huang, Z., Ma, J., Burke, S. L., Karnachi, P., Rhodes, K. J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.045 · Cited by 39
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors
Tauro, M., Laghezza, A., Loiodice, F., Agamennone, M., Campestre, C., & Tortorella, P. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.054 · Cited by 38
Collagenases and their inhibitors: a review
Wu, S., Zhou, X.-W., Jin, Z., & Cheng, H. (2023) · Collagen and Leather · doi:10.1186/s42825-023-00126-6 · Cited by 49
Mechanisms of Metal-Dependent Hydrolases in Metabolism
Hernick, M., & Fierke, C. A. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00178-7 · Cited by 37
Rubino, M. T., Agamennone, M., Campestre, C., Fracchiolla, G., Laghezza, A., Loiodice, F., Nuti, E., Rossello, A., & Tortorella, P. (2009) · ChemMedChem · doi:10.1002/cmdc.200800324 · Cited by 33
Wang, F., Chen, C., Liu, X., Yang, K., Xu, X., & Yang, H. (2015) · Journal of Virology · doi:10.1128/jvi.02685-15 · Cited by 31
Pardo-Jiménez, V., Navarrete-Encina, P. A., & Díaz-Araya, G. (2019) · Molecules · doi:10.3390/molecules24040739 · Cited by 33
“Polyphenols are also recognized for their antioxidant activity in addition to exhibiting antimicrobial and anticancer properties [41,44].”
BackgroundKhodaverdian, V., Tapadar, S., MacDonald, I. A., Xu, Y., Ho, P.-Y., Bridges, A. E., Rajpurohit, P., Sanghani, B. A., Fan, Y., Thangaraju, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39214-1 · Cited by 32
Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury
Skrypnyk, N. I., Sanker, S., Skvarca, L. B., Novitskaya, T., Woods, C., Chiba, T., Patel, K. Y., Goldberg, N. D., McDermott, L. A., Vinson, P. N., et al. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00503.2015 · Cited by 32
Jiao, S., Peng, P., Chang, J., Liu, M., Yu, J., Zhou, L., & Sun, X. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.064 · Cited by 31
Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity
Tauro, M., Laghezza, A., Loiodice, F., Piemontese, L., Caradonna, A., Capelli, D., Montanari, R., Pochetti, G., Pizio, A. D., Agamennone, M., et al. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1217853 · Cited by 31
“N-(3-hydroxyphenyl)-4-diphenylsulfonamide (21)”
MMP-13 selective isonipecotamide α-sulfone hydroxamates
Kolodziej, S. A., Hockerman, S. L., DeCrescenzo, G. A., McDonald, J. J., Mischke, D. A., Munie, G. E., Fletcher, T., Stehle, N. W., Swearingen, C., & Becker, D. P. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.111 · Cited by 29
Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy
Schmitt, C., Voegelin, M., Marin, A., Schmitt, M., Schegg, F., Henon, P. R. G., Guénot, D., & Tarnus, C. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.12.038 · Cited by 29
Investigating chelating sulfonamides and their use in metalloproteinase inhibitors
Tanakit, A., Rouffet, M., Martin, D. P., & Cohen, S. M. (2012) · Dalton Transactions · doi:10.1039/c2dt12373h · Cited by 28
Self-citationInvestigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins
Čapková, K., Salzameda, N. T., & Janda, K. D. (2009) · Toxicon · doi:10.1016/j.toxicon.2009.03.016 · Cited by 28
“Among the variety of groups that coordinate zinc via mono or bidentate modes (Jacobsen et al., 2007), the moiety that is of particular interest to our laboratory is the hydroxamate.”
BackgroundKesharwani, S., & Sundriyal, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113055 · Cited by 27
Muthyala, R., Shin, W. S., Xie, J., & Sham, Y. Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.065 · Cited by 26
Identification of Novel Matrix Metalloproteinase Inhibitors by Screening of Phenol Fragments Library
Rubino, M. T., Maggi, D., Laghezza, A., Loiodice, F., & Tortorella, P. (2011) · Archiv der Pharmazie · doi:10.1002/ardp.201000350 · Cited by 26
A novel amino-benzosuberone derivative is a picomolar inhibitor of mammalian aminopeptidase N/CD13
Maiereanu, C., Schmitt, C., Faux, N., Nouën, D. L., Defoin, A., & Tarnus, C. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.089 · Cited by 31
Metal Compounds as Enzyme Inhibitors
Gasser, G., & Metzler‐Nolte, N. (2011) · doi:10.1002/9783527633104.ch12 · Cited by 25
Starus, A., Nocek, B. P., Bennett, B., Larrabee, J. A., Shaw, D. L., Sae-Lee, W., Russo, M. T., Gillner, D., Makowska-Grzyska, M., Joachimiak, A., et al. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00475 · Cited by 24
Villalta-Romero, F., Gortat, A., Herrera, A. E., Arguedas, R., Quesada, J., Melo, R. L. D., Calvete, J. J., Montero, M. L., Murillo, R., Rucavado, A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300068r · Cited by 24
‘Unconventional’ Coordination Chemistry by Metal Chelating Fragments in a Metalloprotein Active Site
Martin, D. P., Blachly, P. G., Marts, A. R., Woodruff, T. M., de Oliveira, C. A. F., McCammon, J. A., Tierney, D. L., & Cohen, S. M. (2014) · Journal of the American Chemical Society · doi:10.1021/ja500616m · Cited by 22
Self-citationHenke, H., Kandioller, W., Hanif, M., Keppler, B. K., & Hartinger, C. G. (2012) · Chemistry & Biodiversity · doi:10.1002/cbdv.201200005 · Cited by 22
Shin, J., Kim, H. S., Vargas, A., Yu, W., Eom, Y. S., Craft, C. M., & Lee, E.-J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167102 · Cited by 22
Gao, B., Tan, C., Roshani, D., Yang, R., Lv, Z., Li, P., & Shang, N. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2438408 · Cited by 27
“The original zinc-binding inhibitors were small-molecule mimics based on natural peptides that chelate the catalytic Zn (II) ion by binding a zinc-binding group (ZBG) such as hydroxamic acid, thereby occupying the active site and inactivating the enzyme (Jacobsen, Lewi, and Cohen 2007).”
Shin, W. S., Bergström, A., Bonomo, R. A., Crowder, M. W., Muthyala, R., & Sham, Y. Y. (2017) · ChemMedChem · doi:10.1002/cmdc.201700182 · Cited by 22
Structure and mechanism of secondary sulfonamide binding to carbonic anhydrases
Baronas, D., Dudutienė, V., Paketurytė, V., Kairys, V., Смирнов, А. В., Juozapaitienė, V., Vaškevičius, A., Manakova, E., Gražulis, S., Zubrienė, A., et al. (2021) · European Biophysics Journal · doi:10.1007/s00249-021-01561-1 · Cited by 18
Kurbanov, E. K., Leverentz, H. R., Truhlar, D. G., & Amin, E. A. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct4001872 · Cited by 18
Levy, R., Sobolev, V. M., & Edelman, M. (2011) · Human Mutation · doi:10.1002/humu.21573 · Cited by 18
“Drugs have already been designed to suppress the activity of zinc-dependent proteins and in doing so, elicit therapeutic effect [Jacobsen et al., 2007].”
BackgroundInfluentialIntroduction to Zinc Enzymes as Drug Targets
Supuran, C. T., & Winum, J. (2009) · doi:10.1002/9780470508169.ch1 · Cited by 17
Giustiniano, M., Tortorella, P., Agamennone, M., Pizio, A. D., Rossello, A., Nuti, E., Gomez-Monterrey, I. M., Novellino, E., Campiglia, P., Vernieri, E., et al. (2013) · Journal of Amino Acids · doi:10.1155/2013/178381 · Cited by 15
Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor
Zhang, H., Huang, Q., Zhai, J. H., Zhao, Y., Zhang, L., Chen, Y., Zhang, R.-W., Li, Q., & Hu, X.-P. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.59 · Cited by 16
Targeting Metalloproteins by Fragment‐Based Lead Discovery
Johnson, S. L., Barile, E., Farina, B., Purves, A., Wei, J., Chen, L., Shiryaev, S. A., Zhang, Z., Rodionova, I. A., Agrawal, A., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01136.x · Cited by 16
Self-citationRevelant, G., Al-Lakkis-Wehbe, M., Schmitt, M., Alavi, S., Schmitt, C., Roux, L., Al-Masri, M., Faux, N., Maiereanu, C., Tarnus, C., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.066 · Cited by 16
Yang, L., Liu, W., Mei, H., Zhang, Y., Yu, X., Xu, Y. F., Li, H., Huang, J. Y., & Zhao, Z. (2015) · MedChemComm · doi:10.1039/c4md00498a · Cited by 14
Hanif, M., Meier, S. M., Adhireksan, Z., Henke, H., Martić, S., Movassaghi, S., Labib, M., Kandioller, W., Jamieson, S. M. F., Hejl, M., et al. (2017) · ChemPlusChem · doi:10.1002/cplu.201700050 · Cited by 14
Expedient on-resin synthesis of peptidic benzimidazoles
Bird, M. J., Silvestri, A. P., & Dawson, P. E. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.062 · Cited by 15
Gresh, N., Pérahia, D., de Courcy, B., Foret, J., Roux, C., Khoury, L. E., Piquemal, J., & Salmon, L. (2016) · Journal of Computational Chemistry · doi:10.1002/jcc.24503 · Cited by 13
Ivković, J., Jha, S., Lembacher‐Fadum, C., Puschnig, J., Kumar, P., Reithofer, V., Gruber, K. F., Macheroux, P., & Breinbauer, R. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202102204 · Cited by 12
Wang, S.-F., Tian, G. R., Zhang, W., & Jin, J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.060 · Cited by 13
Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group
Li, F., Chvyrkova, I., Terzyan, S. S., Wakeham, N., Turner, R. T., Ghosh, A. K., Zhang, X. C., & Tang, J. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-3893-7 · Cited by 12
“Hydroxamic acid is the most commonly used chelating group in the inhibitors for metalloprotease, including LF (Brown et al. 2006; Jacobsen et al. 2007).”
InfluentialFrant, J., Veerendhar, A., Chernilovsky, T., Nedvetzki, S., Vaksman, O., Hoffman, A., Breuer, E., & Reich, R. (2011) · ChemMedChem · doi:10.1002/cmdc.201100153 · Cited by 12
Cyclopentadienyl and indenyl molybdenum(II) complexes bearing planar N,N,N-chelating ligands
Honzı́ček, J., Honzíčková, I., Vinklárek, J., & Růžičková, Z. (2014) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2014.09.028 · Cited by 12
A Macrophage Cell Model for Selective Metalloproteinase Inhibitor Design
Jacobsen, F. E., Buczynski, M. W., Dennis, E. A., & Cohen, S. M. (2008) · ChemBioChem · doi:10.1002/cbic.200800148 · Cited by 14
Self-citationEffect of donor atom identity on metal-binding pharmacophore coordination
Dick, B. L., Patel, A., McCammon, J. A., & Cohen, S. M. (2017) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-017-1454-3 · Cited by 12
Self-citationKhoury, L. E., Naseem‐Khan, S., Kwapień, K., Hobaika, Z., Maroun, R. G., Piquemal, J., & Gresh, N. (2017) · Journal of Computational Chemistry · doi:10.1002/jcc.24830 · Cited by 12
Chiu, T.-L., & Amin, E. A. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300121p · Cited by 11
Albrecht, S. J. ‐., Salomon, E., Defoin, A., & Tarnus, C. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.06.041 · Cited by 11
Williams, S., de Oliveira, C. A. F., Vazquez, H., & McCammon, J. A. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01060.x · Cited by 11
Shakil, M. S., Parveen, S., Rana, Z., Walsh, F. P., Movassaghi, S., Söhnel, T., Azam, M., Shaheen, M. A., Jamieson, S. M. F., Hanif, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9020123 · Cited by 10
“HPs have attracted increasing interest due to their wide-ranging biomedical applications including as antibacterial [1,5,6] and antiviral agents [6], anthrax lethal factor inhibitors [1,6], magnetic resonance imaging contrast agents [7–14], matrix metalloprotein inhibitors [2,15,16], receptors for Li+ or Na+ [17–19],…”
BackgroundHonzíčková, I., Honzı́ček, J., Vinklárek, J., & Zdenka Padelkova, B. (2014) · Polyhedron · doi:10.1016/j.poly.2014.06.045 · Cited by 10
Arshad, J. Z., & Hanif, M. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00175f · Cited by 10
Phenylethylene glycol-derived LpxC inhibitors with diverse Zn2+-binding groups
Galster, M., Löppenberg, M., Galla, F., Börgel, F., Agoglitta, O., Kirchmair, J., & Holl, R. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.12.011 · Cited by 10
“(S)-2-{2-Hydroxy-1-[4-(phenylethynly)phenyl]ethoxy}acetic acid (13)”
Inhibition and Activity Regulation of Bacterial Collagenases
Schönauer, E., & Brandstetter, H. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_9 · Cited by 8
Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells
Harel, E., Rubinstein, A., Chen, W., Breuer, E., & Tirosh, B. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.048 · Cited by 8
Martin, D. P., Puerta, D. T., & Cohen, S. M. (2014) · doi:10.1002/9781118697191.ch14 · Cited by 8
Self-citationDesign, Synthesis and Evaluation of Fe-S Targeted Adenosine 5′-Phosphosulfate Reductase Inhibitors
Paritala, H., Suzuki, Y., & Carroll, K. S. (2015) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2014.978012 · Cited by 8
“Small molecules that harbor groups that chelate essential metal ions serve as effective inhibitors [34].”
Background
Metadata
- Authors
- Jacobsen, F. E., Lewis, J. A., & Cohen, S. M.
- Affiliations
- University of California San Diego (US)
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2007-01-30
- Volume
- 2
- Issue
- 2
- Pages
- 152-171
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2102128466
- Cited by
- 132
- References
- 175
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 9 · 2016: 6 · 2015: 11 · 2014: 7 · 2013: 8 · 2012: 15
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ChemMedChem (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- small molecule inhibitors, matrix metalloproteinases, histone deacetylase, anthrax lethal factor, bioinorganic chemistry, coordination chemistry
- MeSH terms
- Animals, Binding Sites, Catalysis, Cells, Cultured, Fibroblasts, Humans, Metalloproteins, Protease Inhibitors, Protein Conformation, Spectrum Analysis, Structure-Activity Relationship, Zinc, Drug Design, Inhibitory Concentration 50, Matrix Metalloproteinases, Myoblasts, Cardiac, Matrix Metalloproteinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.